SCHEMBL5582010

SCHEMBL5582010

CNc1ncc2c(-c3ccc(Cl)cc3)cc(-c3ccc(C(=O)O)cc3)c(OC)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 4/20 0.47
CSNK2B P67870 4/20 0.47
CSNK2A1 P68400 6/20 0.44
MAP4K4 O95819 3/20 0.42
LRRK2 Q5S007 1/20 0.40
SRD5A2 P31213 1/20 0.39
TBK1 Q9UHD2 1/20 0.39
NEK2 P51955 1/20 0.38
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
PTK2 Q05397 1/20 0.37
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582255 0.94 CSNK2A1 (0.43) CSNK2A2CSNK2BCSNK2A1MAP4K4LRRK2
SCHEMBL5582330 0.92 CSNK2A1 (0.48) CSNK2A2CSNK2BCSNK2A1MAP4K4TBK1
SCHEMBL5582267 0.91 CSNK2A1 (0.46) CSNK2A2CSNK2BCSNK2A1MAP4K4LRRK2
SCHEMBL5581713 0.91 CSNK2A1 (0.42) CSNK2A2CSNK2BCSNK2A1MAP4K4LRRK2
SCHEMBL5582212 0.91 CSNK2A1 (0.49) CSNK2A2CSNK2BCSNK2A1MAP4K4LRRK2
SCHEMBL5582325 0.91 KMO (0.43) CSNK2A2CSNK2BCSNK2A1MAP4K4LRRK2
SCHEMBL5582013 0.91 CSNK2A1 (0.51) CSNK2A2CSNK2BCSNK2A1LRRK2
SCHEMBL5582036 0.90 PTPN11 (0.43) CSNK2A2CSNK2BCSNK2A1MAP4K4LRRK2
SCHEMBL5581859 0.88 MAP4K4 (0.47) CSNK2A2CSNK2BCSNK2A1MAP4K4LRRK2
SCHEMBL5582062 0.87 MKNK1 (0.44) CSNK2A2CSNK2BCSNK2A1PTK2TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 CSNK2A2 467/4885CSNK2B 662/4885CSNK2A1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.